GlassScriptPhysician profile
Praveen Jetty
NPI 1174613160
$9,819.41
in general payments reported to CMS, 2019-2025
25 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $1,368 · 2021: $1,932 · 2022: $1,192 · 2023: $1,232 · 2024: $1,364 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,078.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,597.84 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,335.00 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $946.68 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $864.02 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $661.00 | 2019-2025 | Austedo Xr |
| Abbvie INC. | $572.77 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $561.50 | 2019-2022 | |
| Axsome Therapeutics, INC. | $491.39 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $457.86 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $439.24 | 2020-2025 | Fanapt |
| Novo Nordisk INC | $246.26 | 2024-2025 | Wegovy |
| Allergan, INC. | $235.56 | 2019-2020 | |
| Lundbeck LLC | $225.40 | 2019-2021 | |
| Corium, LLC | $217.45 | 2022-2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $159.12 | 2024-2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $124.99 | 2024 | Kisunla |
| Collegium Pharmaceutical, INC. | $124.26 | 2025 | Jornay Pm |
| Indivior INC. | $96.92 | 2019-2023 | Perseris |
| Ucb, INC. | $85.02 | 2025 | Nayzilam |
| Tris Pharma INC | $85.02 | 2023 | Quillivant, Quillichew Er, Dyanavel Xr |
| Neuronetics, INC. | $76.16 | 2019-2021 | |
| Eisai INC. | $70.05 | 2020 | |
| Merck Sharp & Dohme LLC | $54.17 | 2019-2021 | |
| Almatica Pharma LLC | $46.34 | 2021-2022 | |
| Noven Therapeutics, LLC | $45.39 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Praveen Jetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.